目的: 分析血清CXC趋化因子配体(CXCL)12、16,同型半胱氨酸(Hcy)水平与急性脑梗死患者梗死面积及短期预后关系。方法: 择取2021年3月-2023年12月在许昌中医院住院的86例急性脑梗死患者为研究组,计算患者梗死面积并对短期预后进行跟踪。另选取我院同期入院健康体检者为对照组(n=86)。对比两组入院时血清CXCL12、CXCL16、Hcy水平;比较不同梗死面积及预后患者入院时血清CXCL12、CXCL16、Hcy水平,并分析其相关性及对预后的预测效能。结果: 与对照组相比,研究组血清CXCL12、CXCL16、Hcy水平显著升高(P＜0.05);研究组不同梗死面积患者入院时血清CXCL12、CXCL16、Hcy水平比较,重度梗死患者＞中度梗死＞轻度梗死患者(P＜0.05);入院时血清CXCL12、CXCL16、Hcy与研究组脑梗死面积均呈正相关(r=0.647、0.651、0.667,P＜0.05);预后不良患者入院时血清CXCL12、CXCL16、Hcy水平显著高于预后良好患者(P＜0.05);入院时血清CXCL12、CXCL16、Hcy水平联合预测预后不良的效能为0.782。结论: 血清CXCL12、CXCL16、Hcy水平与急性脑梗死患者梗死面积及预后相关,可通过检测其水平预测患者预后效果。

Objective: To analyze the relationship between serum CXC chemokine ligand (CXCL) 12,16, homocysteine (Hcy) levels and infarct size and short-term prognosis in patients with acute cerebral infarction. Methods: Eighty-six patients with acute cerebral infarction who were hospitalized in Xuchang Hospital of Traditional Chinese Medicine from March 2021 to December 2023 were selected as the study group. The infarct size of the patients was calculated and the short-term prognosis was tracked. In addition, the healthy subjects admitted to our hospital during the same period were selected as the control group (n=86). The levels of serum CXCL12, CXCL16 and Hcy were compared between the two groups at admission. The levels of serum CXCL12, CXCL16 and Hcy in patients with different infarct size and prognosis at admission were compared, and their correlation and predictive efficacy for prognosis were analyzed. Results: Compared with the control group, the serum levels of CXCL12, CXCL16, and Hcy were significantly elevated in the study group (P＜0.05). Upon admission, the serum levels of CXCL12, CXCL16, and Hcy were higher in patients with severe infarction than those with moderate infarction, which were in turn higher than those in patients with mild infarction (P＜0.05). There was a positive correlation between the serum levels of CXCL12, CXCL16, and Hcy and the infarct size at admission (r=0.647, 0.651, 0.667, respectively, P＜0.05). The levels of serum CXCL12, CXCL16 and Hcy in patients with poor prognosis were significantly higher than those in patients with good prognosis (P＜0.05). The combined efficacy of serum CXCL12, CXCL16 and Hcy levels at admission to predict poor prognosis was 0.782. Conclusion: The levels of serum CXCL12, CXCL16, and Hcy are correlated with the infarct size and prognosis of patients with acute cerebral infarction, and the prognosis of patients can be predicted by detecting their levels.